Citable filing context

UNH filing events and research context

Server-rendered

UNH's research view summarizes recent SEC filing context, starting with other from May 11, 2026.

UNH filing events and research context
FiledItemContext
May 11, 2026otherUNH senior leaders will present at the Bank of America Securities Health Care Conference on May 12, 2026.
Apr 21, 2026earningsUnitedHealth Group announced its first quarter 2026 financial results.
Mar 9, 2026otherUNH senior leaders to present at Barclays 28th Annual Global Healthcare Conference on March 10, 2026.
Apr 21, 2026Guidance: adjusted_eps18.25 to not reported
Apr 21, 2026Guidance: common_stock_repurchase2.00 to not reported
Apr 21, 2026Guidance: debt_to_capital_ratio40.00 to not reported
May 5, 2026mda_quarterlyUnitedHealth Group actively managed its capital structure through significant share repurchases during the first quarter of 2026. In March, the company repurchased 1.7 million shares of common stock at an average price of $285.68 per share. These transactions were executed as part of publicly announced programs, specifically utilizing forward share repurchase contracts with a counterparty. This method provides strategic flexibility, allowing the company to manage the timing and execution of share acquisitions while potentially mitigating market impact. As of March 31, 2026, a substantial 19.3 million shares remained authorized for repurchase under the existing programs, indicating considerable capacity for future capital deployment. The Board of Directors underscored its robust, long-term commitment to shareholder returns in June 2024 by authorizing an additional 35 million shares for repurchase. This new authorization supplemented any remaining capacity from a prior 2018 program. Critically, the overall repurchase program has no established expiration date and can be further amended to increase authorized shares, signaling a sustained strategy to optimize capital allocation, reduce the outstanding share count, and enhance earnings per share.
Mar 2, 2026businessThe provided text does not contain the "Item 1 (Business Description)" section. Instead, it details information regarding executive compensation, equity compensation plans, security ownership, related party transactions, principal accountant fees, and financial statements for the parent company only. It also includes extensive details on various equity award agreements (Restricted Stock Units, Nonqualified Stock Options, Performance-Based Restricted Stock Units) outlining vesting schedules, forfeiture conditions, change-in-control provisions, and restrictive covenants such as non-solicitation, non-competition, and non-disclosure clauses applicable to employees, along with state-specific exceptions to these covenants. The financial data presented is limited to the parent company's condensed balance sheets, statements of comprehensive income, and cash flows, not the consolidated business operations.

Source: SEC EDGAR filing text and events; period May 11, 2026; filed May 11, 2026.

Continue research

Keep researching UNH

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →
AMGN
AMGEN INC
$186.59B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →